There are currently 1471 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
NCT06365853
Recruiting
The purpose of this study is to evaluate the incidence rate and severity of prespecified mirvetuximab soravtansine (MIRV)-related ocular treatment-emergent adverse events (TEAEs) and assess prophylaxis strategies in all participants (symptomatic and asymptomatic) undergoing prospective ophthalmic evaluation with recurrent ovarian cancer (participants with either platinum-sensitive ovarian cancer \[PSOC\] or platinum-resistant ovarian cancer \[PROC\]) with high folate receptor alpha (FRα) express... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: UT Southwestern Medical Center /ID# 269341, Dallas, Texas
Conditions: Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
Register for Updates
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150
Recruiting
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: UT Southwestern, Dallas, Texas
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
Home-based Cardiac Rehabilitation in Heart Failure
NCT06349941
Recruiting
This study evaluates a mobile health (mHealth) home-based cardiac rehabilitation program for patients with heart failure. We will stratify randomization between rural and urban populations, with the goal to assess implementation of cardiac rehabilitation across these two geographic areas. . The study will randomize 332 patients with heart failure (ejection fraction ≥35%) who are not eligible for center-based rehabilitation to either a 12-week mHealth cardiac rehabilitation program or an attentio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas +1 locations
Conditions: Heart Failure
Register for Updates
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
NCT03932773
Recruiting
The purpose of this study is to examine the benefits of combining repetitive Transcranial Magnetic Stimulation (rTMS) coupled with Cognitive Processing Therapy (CPT) in treating combat-related Posttraumatic Stress Disorder (PTSD) symptoms. The study will also examine change in depression, psychosocial functioning, and neurophysiological (i.e., electroencephalography and magnetic resonance images) measures.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
08/15/2025
Locations: The University of Texas at Dallas, Dallas, Texas
Conditions: Post Traumatic Stress Disorder
Register for Updates
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
NCT04704921
Recruiting
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (anti-VEGF)... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
08/15/2025
Locations: Texas Retina Associates - Dallas /ID# 256133, Dallas, Texas
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Register for Updates
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
NCT05183035
Recruiting
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.
Gender:
ALL
Ages:
Between 29 days and 21 years
Trial Updated:
08/15/2025
Locations: Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas
Conditions: Acute Myeloid Leukemia
Register for Updates
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
NCT05863351
Recruiting
This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where it first started (primary site) to a limited (2-5) number of places in the body (metastatic). Study doctors want to find out if this approach is better or worse than the usual approach for metastatic kidney cancer. The usual approach is defined as the care most people get... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: UT Southwestern Simmons Cancer Center - RedBird, Dallas, Texas +1 locations
Conditions: Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Register for Updates
Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)
NCT06829537
Recruiting
This is a non-interventional study to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) and will enroll approximately 1000 patients at approximately 45 sites in the United States (US). Each patient will have an initial visit for screening. After eligibility is confirmed, a limited exam will be performed and demographic and medical history will be collected. Non-fasting labs and a urine collection will also be done. A second visit will be a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Site 370, Dallas, Texas
Conditions: Resistant Hypertension, Hypercortisolism
Register for Updates
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
Recruiting
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Conditions: Smoldering Plasma Cell Myeloma
Register for Updates
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04423211
Recruiting
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the pr... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: UT Southwestern Simmons Cancer Center - RedBird, Dallas, Texas +1 locations
Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
NCT04248452
Recruiting
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, wor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Parkland Memorial Hospital, Dallas, Texas +1 locations
Conditions: Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Oligometastatic Esophageal Adenocarcinoma, Oligometastatic Gastric Adenocarcinoma, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
Register for Updates
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
NCT04375033
Recruiting
VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous (in the belly area) formulation of buprenorphine at a target dose of 300mg is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation at a target dose of 16-32 mg (standard of care). This is an open-label, randomized, controlled trial including 952 Veterans with opioid use disorder (OUD) recruited over 7 years a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas
Conditions: Opioid Use Disorder
Register for Updates